Clinical trial
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After…
NCT00067314 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00067314 |
|---|---|
| Title | Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy |
| Official title | A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Edotecarin |
| Enrollment | 65 |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Aug 18, 2003 |
| Last update posted | Jan 18, 2012 |
| Countries | Australia, Belgium, France, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: